Volitinib is a selective inhibitor of c-Met tyrosine kinase, primarily investigated for its antitumor activity. It has shown promise in the treatment of cancers driven by c-Met pathway dysregulation, such as certain types of non-small cell lung cancer (NSCLC), particularly those with c-Met exon 14 skipping mutations. It is also being studied in papillary renal cell carcinoma and other solid tumors where c-Met signaling plays a key oncogenic role. Due to its high selectivity, volitinib may offer improved safety and efficacy profiles compared to broader kinase inhibitors, making it a candidate for targeted therapy in precision oncology. Clinical development has focused on patients with specific genetic alterations to maximize therapeutic response.